Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
暂无分享,去创建一个
Christoph Grundner | Joseph Sodroski | J. Sodroski | J. Mascola | R. Wyatt | M. Louder | Yuxing Li | Xinzhen Yang | Yuxing Li | Richard Wyatt | C. Grundner | Xinzhen Yang | Mark Louder | John Mascola
[1] E. Fenyö,et al. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. , 1997, Virology.
[2] D. Montefiori,et al. ANTIBODY-DEPENDENT ENHANCEMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION , 1988, The Lancet.
[3] P. Earl,et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities , 1994, Journal of virology.
[4] J. Mascola,et al. Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells , 2002, Journal of Virology.
[5] J. Sodroski,et al. Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin , 2002, Journal of Virology.
[6] J. Sodroski,et al. Stabilization of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers by Disulfide Bonds Introduced into the gp41 Glycoprotein Ectodomain , 1998, Journal of Virology.
[7] J. Sodroski,et al. Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins , 2000, Journal of Virology.
[8] J. Levy,et al. The FC and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. , 1989, Disease markers.
[9] W A Hendrickson,et al. Energetics of the HIV gp120-CD4 binding reaction. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[10] J. Mascola,et al. Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.
[11] M. Champe,et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 , 1990, Nature.
[12] Q. Sattentau,et al. HIV-1 antibody — debris or virion? , 1997, Nature Medicine.
[13] K. Sikora,et al. Human monoclonal antibodies. , 1984, Nature.
[14] Abraham Pinter,et al. Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades , 2002, Journal of Virology.
[15] J. Sodroski,et al. Improved Elicitation of Neutralizing Antibodies against Primary Human Immunodeficiency Viruses by Soluble Stabilized Envelope Glycoprotein Trimers , 2001, Journal of Virology.
[16] F. Ennis,et al. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. , 1988, Science.
[17] J. Mascola,et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.
[18] D. Montefiori,et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. , 1997, The Journal of infectious diseases.
[19] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[20] D. Ho,et al. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[21] H. Schuitemaker,et al. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera , 1995, Journal of virology.
[22] C. Barbas,et al. Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies , 1998, Journal of Virology.
[23] J. Sodroski,et al. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.
[24] J. Sodroski,et al. Solid-Phase Proteoliposomes Containing Human Immunodeficiency Virus Envelope Glycoproteins , 2002, Journal of Virology.
[25] J. Sodroski,et al. CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization , 1998, Journal of Virology.
[26] Ying Sun,et al. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates , 1995, Journal of virology.
[27] K. Steimer,et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. , 1997, Vaccine.
[28] J. Binley,et al. A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.
[29] D. Montefiori,et al. Induction of immune responses to HIV‐1 by canarypox virus (ALVAC) HIV‐1 and gp120 SF‐2 recombinant vaccines in uninfected volunteers , 1998, AIDS.
[30] J. Sodroski,et al. Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution , 2000, Journal of virology.
[31] A. Trkola,et al. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex , 1997, Journal of virology.
[32] J. Hansen,et al. Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection , 1995, Journal of virology.
[33] Peter D. Kwong,et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.
[34] Q. Sattentau,et al. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer , 1995, The Journal of experimental medicine.
[35] J. Heeney,et al. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. , 1994, Vaccine.
[36] D R Burton,et al. A model for neutralization of viruses based on antibody coating of the virion surface. , 2001, Current topics in microbiology and immunology.
[37] J. Moore,et al. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.
[38] J. Mascola,et al. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. , 1994, The Journal of infectious diseases.
[39] J. Kappes,et al. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes , 1991, Journal of virology.
[40] D R Burton,et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.
[41] C. Cheng‐Mayer,et al. Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.
[42] A. Trkola,et al. Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines , 1998, Journal of Virology.
[43] K. Yoon,et al. Antibody-dependent enhancement of virus infection and disease. , 2003, Viral immunology.